TFEB-Mediated Activation of the Autophagy-Lysosome Pathway in Dopaminergic Neurons in Fragile X Syndrome

Francesco Longo and Charlène Perian working in a laboratory at Gothenburg University
FRAXA-funded researchers Francesco Longo, PhD, and Charlène Perian, PhD, in the lab at Gothenburg University.

Francesco Longo, PhD
Principal Investigator

Charlène Perian, PhD
FRAXA Postdoctoral Fellow

Gothenburg University
Gothenburg, Sweden

2026-2027 Grant Funding: $100,000

Summary

This team will investigate whether problems in the autophagy-lysosome pathway contribute to altered dopamine signaling and behavioral inflexibility in fragile X syndrome. Using mouse models, the researchers will test whether activating TFEB can restore dopamine function and improve behavioral flexibility, highlighting a potential new therapeutic approach for Fragile X.

The Science

by Charlene Perian, PhD, and Francesco Longo, PhD

Individuals with Fragile X syndrome (FXS) often experience behavioral inflexibility, including repetitive behaviors and difficulty adapting to change, which can significantly affect daily life for both individuals and their families. This project examines whether problems in the autophagy-lysosome pathway (ALP) — a system that helps brain cells clear excess proteins — contribute to altered dopamine signaling and behavioral rigidity in Fragile X. Given the central role of dopamine signaling in motivation, learning, and behavioral flexibility, disruptions in this system may contribute directly to the behavioral symptoms seen in Fragile X syndrome.

Using mouse models, this study will investigate whether boosting autophagy through a key regulator called TFEB can restore dopamine function and improve behavioral flexibility. By targeting this fundamental cellular process, the study aims to identify a promising new therapeutic strategy that could make daily life easier for individuals with Fragile X syndrome.